[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneurysmal-subarachnoid-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneurysmal-subarachnoid-hemorrhage":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,44,72,95,121,142,163,183,213,234,276,300,324,350,374,404,430,455,480,513,538,569,589,614,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100651462","prevention-of-ischemia-in-aneurysmal-subarachnoid-hemorrhage-through-remote-ischemic-preconditioning-100651462",false,"NCT07761520","Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning","Remote Ischemic Preconditioning (RIPC) and Aneurysmal Subarachnoid Hemorrhage (SAH)","HMA","Inclusion Criteria:\n\n* Age over 18 years\n* Hospitalization for aneurysmal subarachnoid hemorrhage confirmed by CT scan and\u002For lumbar puncture\n* Confirmation of intracranial aneurysm by CT angiography and\u002For cerebral angiography\n* Written informed consent obtained from the patient or legal representative\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Skin, orthopedic, or vascular conditions of the limbs contraindicating ischemic preconditioning (e.g., ulcers, fractures, deep vein thrombosis)\n* Pregnancy\n* Withdrawal of informed consent","ALL","18 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"NA","Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke caused by bleeding around the brain. Despite early treatment of the initial hemorrhage, many patients develop delayed cerebral ischemia several days later, which is a major cause of neurological disability, cognitive impairment, and mortality. Current preventive and therapeutic strategies are only partially effective, highlighting the need for new treatment approaches.\n\nThis study investigates a simple, non-invasive technique called remote ischemic preconditioning (RIPC). RIPC consists of brief, repeated cycles of limb ischemia and reperfusion induced by a blood pressure cuff. RIPC is thought to activate endogenous protective mechanisms that may improve the brain's tolerance to ischemia. Although beneficial effects have been reported in experimental models and cardiovascular diseases, its clinical efficacy in aneurysmal SAH remains uncertain.\n\nIn this randomized, controlled, single-blinded, multicenter study, adult patients admitted with aneyrysmal SAH will be randomly assigned to receive RIPC or a sham procedure. The RIPC group will undergo cycles of brief lower-limb ischemia using a pressure cuff, while the sham group will receive an identical procedure without inducing ischemia. Patients and neurologists assessing outcomes will remain blinded to group allocation.\n\nThe intervention will be performed every two days from day 2 to day 10 after hemorrhage. Neurological outcome will be assessed at 3 months using the modified Rankin Scale. Secondary outcomes include mortality at 3 months, long-term neurological and cognitive function outcomes at 12 months, and the incidence of adverse events related to the procedure.\n\nIf effective, RIPC could become a simple, low-cost, widely accessible method to reduce disability after SAH. The results may help improve future treatment strategies for this severe condition.",[28],"Aneurysmal Subarachnoid Hemorrhage",[30,31],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Remote Ischemic Preconditioning (RIPC)","NOT_YET_RECRUITING","2026-08-11",{"date":35,"type":36},"2026-08-12","ACTUAL",{"date":38,"type":22},"2026-09",{"date":40,"type":22},"2029-09",{"name":42,"class":43},"Centre Hospitalier Universitaire de Nice","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":71},"100603067","the-effect-of-transcutaneous-vagal-nerve-stimulation-tvns-on-cerebral-vasospasm-secondary-to-aneurysmal-subarachnoid-hemorrhage-100603067","NCT07131696","The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Provision of signed and dated informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female\n* 18-65 years of age\n* Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage\n* Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage\n* For females of reproductive potential: negative pregnancy test at time of treatment.\n* Plan to undergo standard of care treatment and follow-up\n\nExclusion Criteria:\n\n* Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)\n* Does not provide consent\n* Posterior circulation aneurysmal subarachnoid hemorrhage\n* Initial aneurysm treatment after post bleed day 1","65 Years",{"count":52,"type":22},10,[25],"The significance of developing a safe and effective therapy for aneurysmal subarachnoid hemorrhage (aSAH) patients suffering cerebral vasospasm (CVS) cannot be overstated. Vasospasm - a clamping down of normal arteries in the days following rupture - remains incredibly challenging to treat.1,2 Current drugs and minimally invasive surgical therapies are helpful, yet woefully insufficient. Symptomatic cerebral vasospasm afflicts about 30% of aneurysmal subarachnoid hemorrhage patients and nearly half will go on to suffer a stroke, despite aggressive medical care.1-3 The autonomic nervous system is a balance between sympathetic (fight or flight) and parasympathetic (rest and digest) influence with sympathetic overactivity and inflammation shown to play an important role in the development and severity of cerebral vasospasm.4,5,17-20 Prior studies of autonomic nervous system neuromodulation highlight its promise as a promising potential avenue to improve morbidity and mortality from CVS in aSAH.6-15 Despite progress, continued high levels of CVS morbidity and mortality stress the urgent need for exploration of neuromodulation therapy.\n\nIn this proposal, the study team will modulate the autonomic nervous system function in aSAH patients using transcutaneous vagal nerve stimulation (tVNS). tVNS involves placement of a stimulation electrode on the external ear to non-invasively stimulate a branch of the vagal nerve and increase parasympathetic influence. This device has FDA approval for epilepsy and cluster headache.\n\nThe study hypothesis is that neuromodulation of the autonomic nervous system with tVNS (increasing parasympathetic influence) reduces sympathetic overactivity and inflammation in aSAH resulting in decreased morbidity of CVS.",[28,56,57,58],"Vasospasm, Cerebral","Transcutaneous Vagal Nerve Stimulation (tVNS)","Endovascular Treatment",[60,61,62],"CVS","aSAH","tVNS","RECRUITING","2026-08-07",{"date":33,"type":36},{"date":67,"type":36},"2026-02-06",{"date":40,"type":22},{"name":70,"class":43},"Marshall Holland",1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":71},"100641500","stellate-ganglion-block-and-prognosis-of-neurological-function-after-subarachnoid-hemorrhage-100641500","NCT07652749","Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage","Effect of Stellate Ganglion Block on the Prognosis of Neurological Function After Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Age range: 18-65 years old;\n* Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);\n* Preoperative Hunt-Hess grade 2-3\n* Sign informed consent.\n\nExclusion Criteria:\n\n* ASA \\> grade IV;\n* Patients with posterior circulation aneurysm;\n* Patients with severe systemic hemorrhagic diseases;\n* Patients with trauma and local infection in the nerve block area;\n* Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);\n* Allergy to known local anesthetics;\n* Pregnant and lactating women.",{"count":80,"type":22},560,[25],"The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH.\n\nIn recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.",[28,84,85],"Stellate Ganglion Block","Neurological Prognosis","2026-06-11",{"date":88,"type":36},"2026-06-17",{"date":90,"type":22},"2026-06-15",{"date":92,"type":22},"2029-03-31",{"name":94,"class":43},"Beijing Tiantan Hospital",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100637311","nitric-oxide-consumption-as-a-predictor-of-vasospasm-in-subarachnoid-hemorrhage-100637311","NCT07614906","Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage","Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage (SAH): a Prospective Observational Study","Inclusion Criteria:\n\n* Adult\n* patient with SAH and with an external ventricular drainage (EVD) placed within 24 hours after the onset of the hemorrhage\n\nExclusion Criteria:\n\n* pregnancy\n* pre-existing neurological comorbidities\n* coagulation disorders\n* anemia\n* absence of a good cranial window to perform Transcranial Doppler (TDC)\n* presence of \\>50% stenosis of carotid arteries confirmed by doppler ultrasound\n* Technical problems on EVD that prevent CSF withdrawals\n\nFor the control group, we will invite to participate patients without neurological comorbidities undergoing spinal anesthesia in the operating room or with a spinal drain for major vascular surgery.",true,{"count":104,"type":22},40,"OBSERVATIONAL","The goal of this observational study is to understand if angiographic cerebral vasospasm (CV) can be predicted by levels of nitric oxide (NO) consumption in patients with aneurysmal subarachnoid hemorrhage (SAH). To reach this goal, the investigators will compare NO consumption levels in SAH and non-SAH patients. NO consumption levels will be analyzed from samples of participants' cerebral spinal fluid (CSF).",[28,108],"Cerebral Vasospasm",[110],"Nitric Oxide Consumption","2026-05-22",{"date":113,"type":36},"2026-05-29",{"date":115,"type":36},"2024-03-03",{"date":117,"type":22},"2027-06",{"name":119,"class":43},"Massachusetts General Hospital",2,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":71},"100612236","dome-only-aneurysm-coiling-in-severe-aneurysmal-subarachnoid-hemorrhage-100612236","NCT07250958","Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage","Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage Observational Study","DOME","Inclusion Criteria:\n\n* 18 years or older\n* CT confirmed aSAH with an angiographically detected aneurysm\n* World Federation of Neurological Sciences (WFNS) aSAH grade 3-5 aneurysm\n* LAR available and gives consent within 72 hours after the onset of aSAH (or last known normal\n\nExclusion Criteria:\n\n* Patients whose aneurysm judged appropriate for balloon-assisted coiling\n* Patients whose aneurysm is bleeding from the \"neck\"\n* Patients who are clinically judged to suffer imminent death within 24 hours.\n* Pregnancy or positive urine pregnancy test",{"count":130,"type":22},30,"The DOME study is a clinical trial exploring a new treatment approach for patients who suffered a severe brain bleed due to an aneurysm.",[28],"2026-05-05",{"date":135,"type":36},"2026-05-11",{"date":137,"type":36},"2026-03-12",{"date":139,"type":22},"2027-01",{"name":141,"class":43},"University of Louisville",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":7},"100537962","phase-4-early-lumbar-drainage-plus-intrathecal-urokinase-in-severe-aneurysmal-subarachnoid-hemorrhage-ld-ituk-100537962","NCT06284642","Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)","Effectiveness and Safety of Early Lumbar Drainage Plus Intrathecal Urokinase Injection in the Treatment of Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK): a Multicentral Randomized Control Trial","Inclusion Criteria:\n\n* Patient's age ≥ 18 years\n* First occurrence of aneurysmal subarachnoid hemorrhage\n* Patients without any craniotomy treatment before onset\n* Hunt-Hess grade III-V\n* mRS grade 0 or 1 before onset\n* Aneurysm treatment within 48 hours of onset\n* Informed consent given by the subject or guardian\n\nExclusion Criteria:\n\n* Subarachnoid hemorrhage caused by arteriovenous malformation or moyamoya disease or other cerebrovascular disease\n* Patients requiring craniotomy to remove intracranial hematoma\n* modified Fisher Scale grade 0\n* Prothrombin time (PT) and activated partial thromboplastin time (APTT) are greater than 2 times the extended range\n* Absolute contraindications for lumbar puncture (e.g., brain hernia, puncture site infection)\n* Patients with a life expectancy of less than 1 year due to other causes\n* Other concomitant serious diseases that are difficult to treat;\n* Pregnant woman\n* Patients who were known to be allergic to urokinase and excipients or had a history of severe allergy and were deemed unsuitable for inclusion by the investigators\n* Participated in another interventional clinical trial within 30 days before randomization\n* Other reasons deemed unsuitable for study participation by the investigator",{"count":150,"type":22},424,[152],"PHASE4","The LD-ITUK is a multicenter, prospective, randomized, double-blind, blind endpoint, placebo-control design trial. All eligible patients with the diagnosis of severe aSAH will be randomly assigned to the treatment group or the placebo group. Patients in the treatment group will receive standard treatment with the addition of lumbar drainage combined with intrathecal urokinase injection started within 24 hours after aneurysm treatment with 30000 IU urokinase, once a day for 3 consecutive days. Patients in the control group will receive standard treatment with the addition of lumbar drainage combined with intrathecal placebo (0.9%NaCl) injection. The primary outcome measure is favorable functional outcome, defined as a score of 0 to 2 on the modified Rankin Scale (mRS), at 6 months after aneurysmal SAH. Primary outcome will be determined by a member of the Independent Committee on Terminal events.",[28],"2026-04-29",{"date":133,"type":36},{"date":158,"type":36},"2024-03-28",{"date":160,"type":22},"2027-12-30",{"name":162,"class":43},"Second Affiliated Hospital of Nanchang University",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":171,"targetDuration":173,"studyType":105,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":71},"100495967","multi-center-registry-cohort-study-on-prognostic-factors-and-prediction-model-construction-in-aneurysmal-sah-100495967","NCT05738083","Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH","Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal Subarachnoid Hemorrhage","PROSAH-MPC","Inclusion Criteria:\n\n* Subarachnoid hemorrhage confirmed by computed tomography (CT);\n* Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage;\n* Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset;\n* Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset.\n\nExclusion Criteria:\n\n* Aneurysm rupture bleeding time exceeding 24 hours before hospital admission;\n* Incomplete image data or blood test information;\n* Long-term use of anticoagulant medications such as aspirin or warfarin;\n* Admitted to hospital with active infectious diseases;\n* long-term anticoagulant drugs such as aspirin, wave dimensions;\n* Presence of other intracranial vascular malformations.",{"count":172,"type":22},5000,"12 Months","PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.",[28],{"date":177,"type":36},"2026-04-30",{"date":179,"type":36},"2018-10-01",{"date":181,"type":22},"2029-12-30",{"name":162,"class":43},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":120},"100630892","phase-1-induced-suppression-of-platelet-activity-in-aneurysmal-subarachnoid-hemorrhage-management-2-ispasm-2-100630892","NCT07493577","Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)","Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2","iSPASM-2","Inclusion:\n\n* Age 18-85\n* Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)\n* SAH attributed to ruptured cerebral aneurysm\n* Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space\n* World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization\n* Onset of symptoms of aSAH (ictus) occurred \\\u003C72 hours prior to presentation\n* If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment\n* All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment\n* Participant can be randomized within 48 hours of aneurysm treatment\n* Participant or participant's legally-authorized representative (LAR) has provided documented informed consent\n\nExclusion:\n\n* Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm\n* Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment\n* Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern\n* Uncontrollable hypertension (\\>180 systolic and\u002For \\>110 diastolic) that is not correctable prior to enrollment\n* Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)\n* A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion\n* New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT\n* Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)\n* Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation\n* Thrombocytopenia (platelet count \\\u003C100,000\u002Fmicroliter (µL) assuming clumping is ruled out\n* Allergy or intolerance to tirofiban\n* Pregnant or lactating\n* Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute \\[ml\u002Fmin\\]) or acute kidney injury (AKI) at study screening. AKI is defined as:\n\n  i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg\u002FdL) or more (26.5 micromoles per liter \\[μmol\u002FL\\] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml\u002Fkg\u002Fhour for at least 6 hours","85 Years",{"count":193,"type":22},82,[195,196],"PHASE1","PHASE2","An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.",[28],[200,201,202,203],"Subarachnoid Hemorrhage","Delayed Cerebral Ischemia","Tirofiban","Brain Aneurysm Rupture","2026-03-23",{"date":206,"type":36},"2026-03-25",{"date":208,"type":22},"2026-07-23",{"date":210,"type":22},"2032-01-23",{"name":212,"class":43},"Dr David Hasan, M.D.",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":232,"locationsCount":71},"100582451","phase-1-tocilizumab-aazg-for-hemorrhage-reduction-of-ischemic-vascular-events-100582451","NCT06863480","Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events","THRIVE: Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events","THRIVE","Inclusion Criteria:\n\n* Adult patients (aged ≥18 years) with Hunt Hess Grade 1-3, Fisher score 3 or 3 and 4, aneurysmal subarachnoid hemorrhage within 24 hours of symptom onset (ruptured aneurysm confirmed by CTA, MRA or DSA)\n* Must have external ventricular drain or lumbar drain, or plan to place an external ventricular drain or lumbar drain.\n* Female subjects of child-bearing potential must have negative pregnancy test\n* Signed informed consent from subject or legally authorized representative\n* Able and willing to comply with followup visits\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, as defined below:\n\nWomen must remain abstinent or use non-hormonal contraceptive methods with a failure rate of 1% per year during the treatment period and for 2 months after the final dose of TYENNE. Women must refrain from donating or storing eggs during the same time period. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n\nThe reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n\nThe following are examples of adequate non-hormonal contraceptive methods: bilateral tubal ligation; male sterilization; copper intrauterine devices; male or female condom with or without spermicide; and cap, diaphragm, or sponge with spermicide.\n\n• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 2 months after the dose of TYENNE to avoid exposing the embryo. Men must refrain from donating sperm during this same period.\n\nThe reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. If required per local guidelines or regulations, information about the reliability of abstinence will be described in the local Informed Consent Form.\n\nExclusion Criteria:\n\n* Evidence for vasospasm or DCI prior to study enrollment\n* Hemodynamically unstable pre-enrollment\n* Severe or unstable concomitant condition or disease (e.g., known significant neurological deficit, cancer, hematologic or coronary disease), or chronic condition (e.g., liver disease, kidney disease, or psychiatric disorder), that may increase the risk associated with study participation, or may interfere with the interpretation of study results\n* Subjects who have received an investigational product or participated in another interventional clinical study within 30 days prior to enrollment.\n* Known hypersensitivity or severe allergic reaction to tocilizumab and\u002For other biologics agents (i.e. shock, anaphylactic reactions)\n* Serious infection defined as pneumonia, sepsis\u002Fseptic shock, and neutropenic fever prior to enrollment\n* Any previous treatment with IL-6 inhibitory therapy (e.g. satralizumab), alemtuzumab, etc.\n* Total body irradiation or bone marrow transplantation within 6 months prior to baseline.\n* Any previous treatment with anti-CD20, anti-CD19, eculizumab, belimumab, interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate within 6 months prior to baseline.\n* Any previous treatment with anti-CD4, cladribine or mitoxantrone within 2 years prior to baseline\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 2 months after TYENNE administration\n* Women of childbearing potential must have a negative serum pregnancy test result prior to initiation of study drug.\n* Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline.\n* Evidence of serious uncontrolled concomitant diseases that may preclude patient participation, such as: other nervous system disease, cardiovascular disease, hematologic\u002Fhematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal\u002Furologic disease, digestive system disease, congenital or acquired severe immunodeficiency.\n* Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.\n* History of diverticulitis that, in the principal investigator's opinion, may lead to increased risk of complications such as lower gastrointestinal perforation.\n* Evidence of active or untreated latent tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection).\n* Evidence of active interstitial lung disease\n* Receipt of any live or live attenuated vaccine within 6 weeks prior to baseline and throughout the duration of the study.\n* History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured).\n* Laboratory exclusion criteria (at screening):\n* White blood cells (WBC) \\\u003C3.0 x103\u002FμL\n* Absolute neutrophil count (ANC) \\\u003C2.0 x103\u002FμL\n* Absolute lymphocyte count \\\u003C0.5 x103\u002FμL\n* Platelet count \\\u003C100 x 103\u002FμL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 times the upper limit of normal (ULN).\n* Patient with known medical history at screening listed for the following must be excluded from this trial:\n* Evidence of chronic active hepatitis B (HBV)\n* Evidence of chronic active hepatitis C (HCV)\n* Positive for hepatitis C virus (HCV) antigen\n* Positive for hepatitis B surface antigen (HBsAg)\n* Known HIV infection.\n* Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment\n* Poor peripheral venous access\n* Serious infection requiring oral or IV antibiotics prior to screening\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study\n* History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree atrioventricular heart block, or evidence of prior myocardial infarction","89 Years",{"count":130,"type":22},[195],"In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.",[28,201],"2026-03-02",{"date":228,"type":36},"2026-03-04",{"date":226,"type":36},{"date":231,"type":22},"2028-10-30",{"name":233,"class":43},"University of Florida",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":242,"targetDuration":244,"studyType":105,"phases":4,"briefSummary":245,"conditions":246,"keywords":251,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":71},"100554080","microvention-aneurysm--stroke-real-life-data-collection-100554080","NCT06494436","Microvention AnEurysm & STroke Real-life Data cOllection","Microvention Aneurysm & Stroke Real-life Data Collection","MAESTRO","Inclusion criteria:\n\n* Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements.\n* For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.\n* For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.\n\nNote: For the purposes of this protocol, ancillary\u002Faccessory devices such as balloon catheters, carotid stent for extracranial stenosis and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.\n\nExclusion Criteria:\n\n* Patient is or is expected to be inaccessible for follow-up.\n* Patient is participating or intends to participate in another study that changes the site practice.\n* Patient is already participating in the MAESTRO study for the same pathology.",{"count":243,"type":22},1000,"18 Months","The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry",[247,248,28,249,250],"Intracranial Aneurysm","Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm Lesion","Ischemic Stroke","Acute Ischemic Stroke",[252,253,254,255,256,257,258,259,260,261,262,263,264,265],"endovascular treatment","stent","flow diverter","hydrocoil","coil","implantable device","FRED","LVIS","WEB","Mechanical Thrombectomy","Aspiration","SOFIA","ERIC","BOBBY","2026-02-05",{"date":268,"type":36},"2026-02-09",{"date":270,"type":36},"2024-12-30",{"date":272,"type":22},"2030-06-30",{"name":274,"class":275},"Microvention-Terumo, Inc.","INDUSTRY",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100547545","phase-2-fludrocortisone-administration-in-aneurysmal-subarachnoid-haemorrhage-100547545","NCT06409364","FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","A Prospective, Blinded, Randomised Clinical Trial of Fludrocortisone Compared With Placebo in Critically Ill Patients Presenting With Aneurysmal Subarachnoid Haemorrhage","FLASH","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosed with subarachnoid haemorrhage from an aneurysm confirmed on computed tomography angiography (CTA) or digital subtraction angiography (DSA) of the intra-cranial arteries\n3. Aneurysm has been secured\n4. Hospital admission for aSAH within 96 hours\n5. Currently being treated in a critical care environment\n\nExclusion Criteria:\n\n1. Unable to receive enteral medications\n2. Pre-existing glucocorticoid or mineralocorticoid treatment\n3. Previous allergic reaction to fludrocortisone\n4. History of cardiac, hepatic, or renal failure\n5. Hypernatremia or hyponatremia (Na\\>145mmol\u002FL or Na\\\u003C125mmol\u002FL) on the most recent blood sample at the time of screening.\n6. Death deemed imminent or inevitable\n7. Pregnancy (confirmed or suspected)\n8. Previous inclusion in the FLASH trial",{"count":285,"type":22},524,[196],"A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage.\n\nThe study aim is to determine if early administration of enteral fludrocortisone in aneurysmal subarachnoid haemorrhage reduce death and dependency at six months.",[28],[61],"2025-12-08",{"date":292,"type":36},"2025-12-16",{"date":294,"type":36},"2025-08-13",{"date":296,"type":22},"2030-07-31",{"name":298,"class":43},"The George Institute",16,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":102,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":308,"targetDuration":173,"studyType":105,"phases":4,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":71},"100613732","aneurysmal-subarachnoid-hemorrhage-multi-omics-research-program-100613732","NCT07270419","Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program","Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program (aSAH-Omics) ：A Multicenter Clinical and Mechanistic Study","aSAH-Omics","Inclusion Criteria:\n\n1. Adult patients aged ≥18 years;\n2. Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;\n3. Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;\n4. Time from onset to aneurysm treatment ≤ 72 hours;\n5. Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization;\n6. Signed informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n1. History of previous intracranial aneurysm surgery or embolization;\n2. Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage;\n3. Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression;\n4. Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation;\n5. Pregnancy or lactation;\n6. Refusal to participate or withdrawal of consent.",{"count":309,"type":22},2000,"Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood.\n\nThis multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.",[28],[313,314,315,28],"Multi-Omics","Prognosis","Complications","2025-11-26",{"date":290,"type":36},{"date":319,"type":36},"2023-11-01",{"date":321,"type":22},"2027-12-01",{"name":323,"class":43},"Xiaolin Chen, MD",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":71},"100406022","phase-2-deferoxamine-in-the-treatment-of-aneurysmal-subarachnoid-hemorrhage-asah-100406022","NCT04566991","Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)","Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (DISH)","DISH","Inclusion Criteria:\n\n* Aneurysmal SAH confirmed with vascular imaging\n* Aneurysm treated with endovascular or microsurgical intervention\n* Hunt-Hess ≤ 4\n* Modified Fisher Grade I-IV\n* Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated\n* First dose of drug can be administered within 24 hours of symptom onset\n* Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1\n* Informed consent obtained by patient or legal authorized representative (LAR)\n\nExclusion Criteria:\n\n* Previous hypersensitivity to or treatment with deferoxamine\n* Presence of giant aneurysm (\\>25 mm in size)\n* Known severe iron deficiency anemia, Hemoglobin (Hgb) g\u002Fdl ≤ 7 or transfusion dependent\n* Irreversibly impaired brainstem function\n* Abnormal renal function, Serum Creatinine\\> 2 mg\u002FdL\n* Pre-existing severe disability, mRS ≥ 2\n* Coagulopathy, including use of anti-platelet or anticoagulant drugs\n* Known severe hearing loss\n* Chronic pulmonary disease that limits basic activities of daily living at baseline, or requires the use of home oxygen.\n* Acute pulmonary disease with the need for any of the following - in a 72 hour period prior to enrollment: \\>4L\u002Fminute nasal cannula (or equivalent O2 delivery via face mask\u002F tent), heated-high flow nasal cannula, noninvasive positive pressure ventilation, and in intubated patients FiO2\\>45% or positive end-expiratory pressure (PEEP) \\> 8cmH2O. This does not include the use of supplemental oxygen in any form for pre-oxygenation, apneic oxygenation, or peri-procedural support alone.\n* Taking iron supplements containing \\> 325 mg of ferrous iron\n* Pregnancy or nursing\n* Life expectancy less than 90 days due to co-morbidities\n* Concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed\n* Prior history of hepatic dysfunction\n* Known cytopenia (platelets \\\u003C 50,000, Absolute neutrophil count \\\u003C 500)\n* Current use of prochlorperazine\n* History of severe psychiatric disorder","80 Years",{"count":334,"type":22},120,[196],"Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals.\n\nThis trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.",[28],[339,340],"Deferoxamine","Placebo","2025-11-21",{"date":343,"type":36},"2025-11-28",{"date":345,"type":36},"2022-03-20",{"date":347,"type":22},"2027-10",{"name":349,"class":43},"Aditya S. Pandey, MD",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":332,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":71},"100612151","phase-3-cilostazol-for-preventing-delayed-cerebral-ischemia-in-aneurysmal-subarachnoid-hemorrhage-100612151","NCT07249853","Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage","Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial","CAPTAIN","Inclusion Criteria:\n\n* Aged 18-80 years.\n* Diagnosed with subarachnoid hemorrhage (SAH) by computed tomography (CT) scan, and the responsible aneurysm is clearly identified by computed tomography angiography (CTA) or digital subtraction angiography (DSA).\n* Received aneurysm coil embolization or craniotomy clipping within 72 hours of symptom onset.\n* Hunt-Hess grade II-IV.\n* No rebleeding or new intracranial hemorrhage is shown on head CT within 6 hours after surgery.\n* Understand and follow the procedures of clinical trial, participate voluntarily and sign the informed consent (the informed consent can be signed voluntarily by the person or guardian)\n\nExclusion Criteria:\n\n* Multiple aneurysms (\\>1aneurysms confirmed by CTA\u002FDSA)\n* Modified Rankin Scale (mRS) score ≥ 3 before onset\n* Patients with contraindications to cilostazol use:\n\n  1. Allergy to cilostazol\n  2. Severe heart failure（New York Heart Association (NYHA) Functional Classification Grade III or IV）\n  3. Coagulation disorders or systemic bleeding (e.g., hemophilia, gastrointestinal bleeding, hemoptysis, etc.)\n  4. Pregnant or lactating women\n* Patients with severe organic diseases and an expected survival time of less than 90 days\n* Severe liver insufficiency or renal insufficiency before randomization\n* Aneurysm treatment requiring the use of other antiplatelet drugs after interventional therapy\n* Currently receiving treatment with other investigational drugs or device trials",{"count":359,"type":22},316,[361],"PHASE3","The investigators propose to conduct a multicenter randomized trial to test whether cilostazol reduces the incidence of delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) and improves patients' neurological prognosis, while assessing its safety.",[28],[28,365,201],"Cilostazol","2025-11-18",{"date":368,"type":36},"2025-11-25",{"date":370,"type":22},"2025-11-30",{"date":372,"type":22},"2027-08-31",{"name":94,"class":43},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100604087","phase-3-cilostazol-with-nimodipine-to-improve-outcome-after-aneurysmal-subarachnoid-hemorrhage-100604087","NCT07144956","Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","Is Adding Cilostazol to Nimodipine Improving Neurological Outcome of Patients With Aneurysmal Subarachnoid Hemorrhage? A Randomized, Double Blind, Placebo-controlled Trial","CASH","Inclusion Criteria:\n\n* Adult patients admitted to an ICU with SAH related to a ruptured cerebral aneurysm occurring within the last 96 hours.\n* Aneurysm successfully secured by surgical clipping or endovascular coiling\n* Consent of the patient or, if not possible, from a proxy (emergency clause).\n* Registration in a national health care system\n\nExclusion Criteria:\n\n* \\- Precritical modified Rankin Scale (mRS) \\> 2\n* Nonaneurysmal SAH\n* Delayed \\>96h admission after first symptoms of SAH\n* Coma defined by GCS of 3-5 with untreatable aneurysm will be excluded\"\n* Known allergy to cilostazol\n* Pregnancy\n* Pre-existing major hepatic, renal, pulmonary or cardiac disease\n* Concomitant use of one other anti-platelet and\u002For anticoagulant agent\n* SAH diagnosed on Lumbar puncture with no evidence of blood on CT.\n* Tutelage or guardianship",{"count":383,"type":22},630,[361],"The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.",[28],[365,388,389,390,391,392,393,394],"Nimodipine","Vasospasm","Modified Rankin Scale (mRS)","Neurological outcome","Double-blind","Randomized Controlled Trial","Multicenter clinical trial","2025-09-04",{"date":397,"type":36},"2025-09-10",{"date":399,"type":22},"2025-12-15",{"date":401,"type":22},"2029-12-14",{"name":403,"class":43},"Centre Hospitalier St Anne",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":332,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":429},"100541420","treatment-of-vasospasm-of-aneurysmal-subarachnoid-hemorrhage-with-intrathecal-nicardipine---fast-it-trial-100541420","NCT06329635","Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial","Trial of Treatment of Vasospasm Associated With Aneurysmal Subarachnoid Hemorrhage With Intrathecal Injection of Nicardipine: a Multi-center, Prospective, Double-blinded, Randomized Controlled Trial","Inclusion criteria:\n\n1. Age 18-80.\n2. Spontaneous SAH confirmed by head CT.\n3. Saccular brain aneurysm is identified and treated, either surgically or endovascularly.\n4. SAH Fisher grade \\>1 or modified Fisher grade \\>0.\n5. EVD placed for acute hydrocephalus, or LD placed for draining bloody CSF as deemed necessary by the treating physician.\n6. Any clinical scenario leading to the diagnosis of possible vasospasm, which includes:\n\n   1. Mean flow velocity of MCA \\>120, or Lindegaard Ratio ( LR ) \\> 3.\n   2. Any intracranial artery including MCA, ACA, PCA, and BA, TCD showed an upward trend of mean flow velocity for 2 consecutive days (\\>25cm\u002Fs\u002Fday).\n   3. Clinical deterioration including mental status change (GCS score decrease \\> 2) and focal neurological deficit unable to be attributed to other known neurological reasons.\n   4. Evidence of vasospasm on CTA or DSA, or ischemic change by CTP, MRI.\n7. Within 14 days of onset of SAH.\n8. Informed consent obtained from the patient or family member.\n\nExclusion criteria:\n\n1. Hunt-Hess Grade 5 or WFNS Grade 5 (no clinical improvement after EVD placement for acute hydrocephalus).\n2. Bacterial or distal aneurysms without subarachnoid hemorrhage in the basal cisterns.\n3. The treating physician determines that the culprit aneurysm has not been fully repaired, with a very high likelihood of rebleeding in the near term.\n4. History of head trauma within the past 3 months.\n5. Any recent brain disease within 3 months, such as tumors, stroke, epilepsy, vasculitis, arteriovenous malformation, hydrocephalus, etc.\n6. History of psychiatric disorders or seizures within 3 months.\n7. Severe concurrent medical conditions.\n8. Pregnant women or those of childbearing potential with a positive urine or serum β-human chorionic gonadotropin (HCG) test.\n9. Lactating women.\n10. Life expectancy of less than 1 year prior to aSAH onset.\n11. Pre-morbid mRS score \\>1.\n12. Participation in another randomized clinical trial that may confound the evaluation of this study.",{"count":412,"type":22},396,[25],"To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.",[28,389],[28,389,417,418,419],"Delayed cerebral ischemia","Nicardipine","Intrathecal injection","2025-09-02",{"date":422,"type":36},"2025-09-08",{"date":424,"type":36},"2024-05-27",{"date":426,"type":22},"2026-05",{"name":428,"class":43},"The Affiliated Hospital Of Guizhou Medical University",28,{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":443,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":71},"100604469","early-blood-pressure-intervention-after-coiling-or-clipping-for-subarachnoid-hemorrhage-100604469","NCT07149922","Early Blood Pressure Intervention After Coiling or Clipping for Subarachnoid Hemorrhage","EPIC-SAH","Inclusion Criteria:\n\n* 1\\) Aged 18-75 years;\n\n  2\\) Patients who underwent clipping or endovascular intervention within 72 hours post-ictus;\n\n  3\\) Intracranial aneurysm diagnosis confirmed by operating surgeons (including neurosurgeons or neurointerventionalists) through imaging findings, intraoperative visualization, or angiography, with subarachnoid hemorrhage (SAH) attributable to the ruptured aneurysm lesion (verified via imaging, xanthochromic cerebrospinal fluid, or intraoperative observation);\n\n  4\\) Hunt-Hess grade 1-4 at onset;\n\nExclusion Criteria:\n\n* 1\\) Presence of untreated intracranial aneurysms with rupture risk;\n\n  2\\) Moderate-to-severe cerebral vasospasm confirmed by pre-enrollment digital subtraction angiography (DSA), transcranial Doppler (TCD), or computed tomography angiography (CTA);\n\n  3\\) Intracranial massive hematoma (e.g., volume \\>30 mL with midline shift \\>5 mm) causing severe cerebral herniation, as evidenced by admission CT or other imaging modalities;\n\n  4\\) Prior cranial neurosurgery for other central nervous system disorders;\n\n  5\\) Comorbid major systemic diseases or multi-organ dysfunction with life expectancy \\\u003C1 year, potentially compromising study implementation or follow-up observations;\n\n  6\\) Poorly controlled hypertension despite regular antihypertensive medication (e.g., systolic blood pressure \\>160 mmHg during pharmacotherapy);\n\n  7\\) Pre-onset modified Rankin Scale (mRS) score \\>2 points, indicating disability from other causes;\n\n  8\\) Intraoperative major complications including but not limited to massive cerebral hemorrhage, hypovolemic shock, or malignant brain swelling;\n\n  9\\) Anticipated inability to complete scheduled follow-up assessments within 180 days;\n\n  10\\) Pregnancy.","75 Years",{"count":439,"type":22},750,[25],"The goal of this clinical trial is to learn if elevating postoperative blood pressure works to improve prognosis in aneurysmal subarachnoid hemorrhage (aSAH) patients. The main questions it aims to answer are:\n\nDoes elevating postoperative blood pressure can improve the prognosis of aSAH ? What safety problems do participants have when received elevating blood pressure measurement?\n\nParticipants will:\n\nReceive elevating or lowering blood pressure therapy in 72 hours after randomization, in order to maintain blood pressure within predefined target ranges Receive follow-up at 30 days, 90 days, and 180 days after randomization",[28,30],[444,445,446,447],"aneurysmal subarachnoid hemorrhage","delayed cerebral ischemia","blood pressure","prognosis","2025-08-24",{"date":420,"type":36},{"date":451,"type":22},"2025-08-31",{"date":453,"type":22},"2028-07-31",{"name":94,"class":43},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":4},"100595325","perfusion-imaging-score-to-predict-delayed-cerebral-ischemia-100595325","NCT07030985","Perfusion Imaging Score to Predict Delayed Cerebral Ischemia","Inclusion Criteria:\n\n* Age \\>18 years with a diagnosis of aSAH\n\nExclusion Criteria:\n\n* chronic kidney disease stage IV\n* pregnancy\n* allergy to iodine that precludes CTP\n* subjects with significant aphasia, blindness, or other factors that limit their participation in the cognitive assessment",{"count":462,"type":22},55,[25],"Aneurysmal subarachnoid hemorrhage (aSAH) is a significant public health concern, annually affecting over 30,000 Americans and ranking among the leading causes of stroke-related life-years lost in individuals aged 65 and younger. Delayed cerebral ischemia (DCI), occurring in 20% to 40% of aSAH survivors, is a major contributor to brain injury and disability. Timely recognition of DCI is crucial for improving neurological outcomes and preventing irreversible cerebral infarction. However, current methods have substantial limitations, hindering early and reliable detection. This proposal seeks to address these challenges through determining the ability of perfusion imaging to predict DCI and correlate with neurological and neuropsychological outcomes.",[28,466],"Cerebral Ischemia",[468,469,470,471],"computed tomography perfusion","brain perfusion","early detection","prediction","2025-06-23",{"date":474,"type":36},"2025-06-26",{"date":476,"type":22},"2025-09",{"date":38,"type":22},{"name":479,"class":43},"Stanford University",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":489,"conditions":490,"keywords":495,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":512},"100504719","study-on-prognosis-of-acutely-ruptured-intracranial-aneurysms-100504719","NCT05851989","Study on Prognosis of Acutely Ruptured Intracranial Aneurysms","SPARTA","Inclusion Criteria:\n\n* Confirmed diagnosis of subarachnoid haemorrhage on CT-scan or lumbar puncture (in the presence of a negative CT-scan)\n* Intracranial aneurysm proven within 6 months to be the cause of subarachnoid haemorrhage\n* Age 18 years or over at presentation.\n* Written informed consent\n\nExclusion Criteria:\n\n* Subarachnoid haemorrhage deemed most likely of 'perimesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)\n* Subarachnoid haemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)\n* Diagnosis of intracerebral arteriovenous malformations or dural arteriovenous fistula.\n* No diagnosis of intracranial aneurysm at 6 months after onset of symptoms.\n* Not mastering the Dutch language",{"count":488,"type":22},880,"The SPARTA study is a prospective multicenter observational trial in the Netherlands with the aim of identifying the best clinical care in patients with aneurysmal subarachnoidal haemorrhage. Differences in outcome between surgical treatment and endovascular treatment will be explored.\n\nFurthermore, cost effectiveness and radiological prognostic factors will be examined.",[28,491,492,493,494],"Endovascular Procedures","Craniotomy","Patient Outcome Assessment","Treatment Outcome",[496,497,498,499,500,501,502],"Aneurysmal subarachnoid hemorrhage","Clipping","Neurosurgery","Coiling","Endovascular treatment","Outcome","Modified Rankin Scale","2025-03-22",{"date":505,"type":36},"2025-03-25",{"date":507,"type":36},"2021-07-14",{"date":509,"type":22},"2034-07-14",{"name":511,"class":43},"Haaglanden Medical Centre",6,{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":71},"100401433","phase-2-improving-outcome-in-subarachnoid-hemorrhage-with-nadroparine-100401433","NCT04507178","Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine","ISCHEMIA","Inclusion Criteria:\n\n* SAH confirmed by CT or lumbar puncture with the causative aneurysm confirmed by CT-A and\u002For digital subtraction angiography\n* Coiling of the causative aneurysm within 72 hours of initial SAH\n* Informed consent within 24 hours after coiling\n\nExclusion Criteria:\n\nStent-assisted coiling\n\n* Use of anticoagulant medication post-coiling for other reasons\n* Contra-indications for LMWH:\n\n  * Previous history of history of heparin-induced thrombocytopenia\n  * (Suspicion of) active arterial or venous bleeding\n  * Previous history of hemorrhagic diathesis due to coagulation disorders (with the ex-ception of disseminated intravascular coagulation)\n  * Severe hypertension: uncontrolled hypertension with a mean arterial pressure \\>135mmHg\n  * Previous history of hypertensive or diabetic retinopathy\n  * Previous history of active infectious endocarditis\n  * Severe renal impairment (creatinine clearance \\\u003C30 mL \u002F min)\n* No proficiency of Dutch or English language",{"count":521,"type":22},100,[196],"Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH) was long thought to be caused by subarachnoid blood-induced vasospasm. Experimental and clinical evidence suggest activation of several pathophysiological pathways, affecting the cerebral microcirculation. Recently, lower in-hospital mortality and less non-home discharge was reported in patients treated with therapeutic low-molecular weight heparin (LMWH), compared to patients with standard, prophylactic LMWH, pointing towards a potential benefit of higher doses of LMWH in the acute course after aSAH. Treatment with therapeutic LMWH might improve clinical outcome in endovascularly treated aSAH patients.\n\nThe primary objective is to evaluate whether aSAH patients treated with therapeutic LMWH have a lower 30-day mortality rate compared to patients treated with prophylactic LMWH. Secondary objectives are to evaluate whether there are significant differences between patients treated with therapeutic and prophylactic LMWH in development of DCI, (hemorrhagic) complications during admission, hydrocephalus, non-home discharge location, quality of life, clinical outcome and cognitive functioning at three and six months, total health care costs.\n\nA single center, prospective, phase II randomized clinical trial in aneurysmal SAH patients ≥18 years old, in whom the causative aneurysm is treated with endovascular coiling less than 72 hours after initial SAH.\n\nPatients are randomized into 2 groups: (1) Therapeutic dose LMWH group: the standard prophylactic dose, administered upon hospital admission, will be replaced by nadroparin s.c. twice daily 5700 IE anti-Xa, starting within 24 hours after coiling and continued until 21 days after ictus of initial SAH. After 21 days, patients will continue with standard care prophylactic dose until discharge or when mobilized for more than 6 hours per day; (2) Control group: standard of care treatment with prophylactic dose of LMWH; nadroparin, s.c. once daily 2850 AxaIU until discharge or when mobilized for at least 6 hours a day.\n\nPrimary outcome: 30-days' mortality. Secondary outcome: DCI, venous thrombo-embolic complications, occurrence of major and non-major bleeding, hemorrhagic complications after external ventricular\u002Flumbar drain (EVD\u002FELD) placement and lumbar puncture (LP), other SAH-related complications, shunt-dependent hydrocephalus, discharge location, quality of life, total health care costs, cognitive functioning, clinical outcome.",[28,201],[526,527,528,445],"nadroparin","subarachnoid hemorrhage","brain ischemia","2025-01-27",{"date":531,"type":36},"2025-01-29",{"date":533,"type":36},"2022-02-02",{"date":535,"type":22},"2027-04-01",{"name":537,"class":43},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":71},"100400125","prevention-of-vasospasm-in-sah-through-csf-treatment-100400125","NCT04490161","Prevention of Vasospasm in SAH Through CSF Treatment","Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Through Treatment With Intravenous Autologous Cerebrospinal Fluid - a Pilot Trial.","PREVAIL","Inclusion Criteria:\n\nAge: \\>18, \\\u003C90\n\n* SAH HH 3 - 5\n* Cerebral saccular Aneurysm\n* Digital subtraction angiography prior to aneurysm repair\n* Aneurysm repair within 72h\n* Modified Fisher Grade 3+4\n* Presence of aneurysm needing treatment (clipping or coiling)\n* Treatment within 24 hours of symptom onset\n* External ventricular drain (clinical need)\n\nExclusion Criteria:\n\n* Non-aneurysmal SAH\n\n  * SAH HH\\\u003C3\n  * Extensive intraventricular haemorrhage (unable to obtain CSF without massive aspiration of clotted blood)\n  * Contraindication for digital subtraction angiography\n  * Aneurysm repair \\>72h after rupture\n  * Signs of radiographic vasospasm upon diagnosis\n  * Presence of systemic or CSF infection\n  * Contraindication for oral Nimodipin\n  * Pregnancy","90 Years",{"count":548,"type":22},20,[25],"The pathophysiological mechanisms of aneurysmal subarachnoid haemorrhage (aSAH) involve early brain injury (EBI) and delayed cerebral ischemia (DCI).\n\nSeveral mechanisms contribute to EBI pathogenesis, including cell death, inflammatory response, oxidative stress, excitotoxicity, microcirculatory dysfunction, microthrombosis and cortical spreading depolarization. All are suggested to be linked due to common pathogenic pathways and direct interaction.\n\nDespite advances in research of diagnostics and treatment strategies, brain injury remains the major cause of death and disability in SAH patients. There is no sufficient treatment of SAH and its devastating consequences known so far. Developing and improving diagnostic methods to monitor SAH patients and to evaluate efficacy of treatment strategies are essential in SAH research. These include neuroimaging, biomarkers, and other parameters such as invasive multimodal neuromonitoring and intraoperative electrophysiological monitoring.\n\nCerebral vasospasm (CV) - mostly responsible for DCI - can be depicted on angiograms. Altogether, tremendous efforts have been taken to conquer the occurrence and sustainability of CV. The mortality of patients suffering aSAH rises up to 50% if the patients' condition is critical (Hunt\\&Hess (HH) Grade 5, WFNS Grade 5, modified Fisher Grade 4).\n\nReports of beneficial outcome in patients with pre-existing CSF shunting have been published. The hypothesis of early CSF reapplication to the bloodstream, in order to prevent CV seems to be positively approved by the mentioned reports. Nevertheless, no data could be found on the mechanisms of action in this phenomenon.\n\nTo confirm the presence of interaction of the mechanisms of EBI and evaluate the application of cerebrospinal fluid (CSF), a pilot clinical trial was planned. Due to the lack of validated animal models for aSAH it is necessary to perform the trial first-in-human. A pilot (proof of concept) trial - is done through inclusion of 10 patients with severe aSAH (≥HH4). According to clinical guidelines, these patients receive external ventricular drainages in order to drain CSF and lower intracranial pressure. An interim analysis of data will be performed after inclusion and treatment of 5 patients. Blood-\u002FCSF-sampling for further analysis will be collected before, during and after treatment according to the study protocol.",[200,552,56,28],"Subarachnoid Hemorrhage, Aneurysmal",[554,555,556,557,558,559],"EVD","Aneurysm","SAH","Subarachnoid hemorrhage","cerebral vasospasm","cerebrospinal fluid","2024-11-25",{"date":562,"type":36},"2024-11-27",{"date":564,"type":36},"2020-01-01",{"date":566,"type":22},"2025-02-01",{"name":568,"class":43},"Medical University Innsbruck",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":71},"100514102","coagulation-disorders-in-ischaemic-and-haemorrhagic-stroke-100514102","NCT05974111","COAgulation Disorders in Ischaemic and Haemorrhagic Stroke","COADIHS","Inclusion Criteria:\n\nPresenting at the hospital with ischaemic stroke, haemorrhagic stroke, aneurysmal subarachnoid haemorrhage or any other type of non-traumatic, intracranial bleeding\n\nIn patients with minor ischemic stroke (NIHSS \\\u003C= 4) only baseline lab sampling will be performed (T0 and T0B).\n\nExclusion Criteria:\n\n* Refusal of participation by patient or legal representative\n* Traumatic intracranial (subdural, subarachnoid, epidural haematoma) bleeding\n* Patients receiving treatment with interference on coagulation (pro \u002F anti) before first sampling: in this group of patients the coagulation assessment at presentation will be excluded, further lab sampling is performed according to protocol.\n* Patients categorized as having stroke mimic will be excluded from analysis afterwards",{"count":577,"type":22},350,"In this study the investigators will assess both procoagulant and anticoagulant pathways using thrombin generation and platelet function tests; as well as neuronal ischemia using cell free DNA in all patients presenting with ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further investigated. As such the investigators aim to characterise the patient's coagulation profile before administration of any treatment. By assessing these pathways the investigators strive to detect specific markers to predict vital and functional outcome at 3 months in these patients. Finally the investigators may provide new pathophysiological insights in the course of disease following these events that can possibly improve future therapeutic strategies.",[249,580,28],"Haemorrhagic Stroke","2024-11-12",{"date":583,"type":36},"2024-11-14",{"date":585,"type":36},"2023-05-02",{"date":451,"type":22},{"name":588,"class":43},"Ziekenhuis Oost-Limburg",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":613},"100384203","phase-2-cerebral-hemodynamic-optimization-by-milrinone-to-prevent-delayed-cerebral-ischemia-100384203","NCT04282629","Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia","Efficacy of 10 Days Intravenous Milrinone Treatment to Optimize Cerebral Hemodynamic and Prevent Delayed Cerebral Ischemia (DCI) in Patients with Severe Subarachnoid Hemorrhage Due to Intracranial Aneurysm Rupture","OPTIMIL","Inclusion Criteria:\n\n* patients with severe SAHa (WFNS IV and V,) whose neurological examination is impossible because of coma (Glasgow coma score of 8 or less) or need for sedation at D3\n* absence of pre-existing neurological handicap (mRS 0-2)\n* major patient (≥ 18 years)\n* affiliation to social security or benefiting through a third person\n* free patient, without tutorship or curatorship or under judicial protection\n* obtaining a signed informed consent by a relative (or the person of trust) after clear and fair information about the study.\n\nExclusion Criteria:\n\n* patients with non-severe SAHa (WFNS I, II and III)\n* Occurrence of a major complication (haemorrhagic or ischaemic) documented during the procedure of securing the aneurysm and endangering the short-term vital prognosis\n* heart failure requiring inotropic administration at the time of randomization\n* ICHT at the time of randomisation (ICP\\> 25 mmHg for at least 20 min)\n* known severe obstructive heart diseases\n* flutter patient or atrial fibrillation\n* hypotension and \u002F or severe hypovolemia with hemodynamic instability\n* septic shock\n* acute \u002F chronic renal insufficiency (Cl \\\u003C50ml \u002F min)\n* major hydroelectrolytic disorders (hypokalemia \\\u003C3 mmol \u002F L)\n* known hypersensitivity to milrinone or any of the excipients\n* early limitation of life-sustaining care\n* pregnancy, breastfeeding\n* permanent contraindications to MRI\n* participation in another clinical interventional study",{"count":598,"type":22},234,[196],"The present study is a randomized, multi-center, double-blind, prospective study that tests the efficacy of intravenous milrinone to optimize cerebral hemodynamic and prevent delayed cerebral ischemia (DCI) during the high-risk period (day 4- day 14) in patients with severe subarachnoid hemorrhage due to intracranial aneurysm rupture (SAHa) (WFNS IV-V). The main objective is to evaluate, in comatose patients and \u002F or sedated on D3 following a severe SAHa (WFNS IV -V), the effect of 10 days of milrinone versus placebo, in addition to the usual management, on the volume of DCI lesions measured on CT scan at 1 month.",[28],[603,389,201],"Milrinone","2024-09-23",{"date":606,"type":36},"2024-09-25",{"date":608,"type":36},"2021-07-25",{"date":610,"type":22},"2025-07",{"name":612,"class":43},"University Hospital, Toulouse",5,{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":635,"leadSponsor":637,"locationsCount":71},"100559049","phase-3-ultra-early-statin-in-patients-with-aneurysmal-subarachnoid-hemorrhage-ue-star-100559049","NCT06559072","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR): a Randomized Controlled Trial","Ue-STAR","Inclusion Criteria:\n\n1. Male or female; Aged ≥18 years\n2. Signs and symptoms presumed aneurysmal subarachnoid hemorrhage, confirmed by radiological evidence\n3. Treatment within 6 h after symptom onset\n\nExclusion Criteria:\n\n1. Treatment with statin prior SAH\n2. Non-aSAH (e.g. traumatic subarachnoid hemorrhage, arteriovenous malformation)\n3. Treatment \\> 6 h after symptom onset\n4. Allergy to statin medications or presence of severe adverse reactions such as abnormal liver function or rhabdomyolysis\n5. Evidence of irreversible brain damage or expected death within 7 days\n6. Known severe liver or kidney disease\n7. Non-compliance with follow-up\n8. Pregnant or breastfeeding\n9. History of severe cranial or psychiatric illness\n10. Concomitant serious systemic disease\n11. Patients with malignant tumors\n12. Currently participating in another clinical trial\n13. Considered unsuitable for the clinical trial by clinical physicians or researchers",{"count":623,"type":22},522,[361],"A researcher-initiated and conducted multicenter, randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage (aSAH).",[200,552,28,627],"Hemorrhage, Aneurysmal Subarachnoid",[444,629,630],"atorvastatin","Atorvastatin Calcium","2024-09-01",{"date":633,"type":36},"2024-09-05",{"date":631,"type":22},{"date":636,"type":22},"2026-09-01",{"name":298,"class":43},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":102,"sex":18,"minAge":19,"maxAge":332,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":71},"100558235","human-albumin-for-clinical-outcome-in-aneurysmal-subarachnoid-hemorrhages-100558235","NCT06548477","Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages","Effectiveness of Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages: A Protocol for Randomized Controlled (Hash) Trial.","HASH","Inclusion criteria\n\n* Age limits of participants will be between 18 and 80 years with either gender (male or female).\n* Clinical presentation with the first of symptom of aSAH must be within 72 hours before randomization.\n* Clinical manifestation must be suggestive of aSAH that may include classical thunderclap headache, cranial nerve deficits, changes in level of consciousness, neck rigidity and neurological deficits.\n* All cases with WFNS grade 1 to 5 (at the time of randomization) will be recruited in the study.\n* Head computed tomography demonstrates evidence of SAH (graded on Claassen's scale).\n* Diagnostic cerebral angiography shows a saccular aneurysm\u002Fs, consistent with clinical presentation of SAH.\n* Definitive treatment of ruptured aneurysm\u002Fs (with clipping or coiling of combined) must be carried out within 72 hours prior to randomization.\n* An informed consent by patient or surrogate representative, must be duly signed and dated.\n\nExclusion criteria\n\n* Timing of first symptom of SAH cannot be reliably ascertained.\n* Cerebral angiogram negative SAH.\n* Cerebral angiography showing mycotic\u002Ftraumatic\u002Ffusiform aneurysm\u002Fs.\n* Symptomatic vasospasm or angiographic (on TCD or CTA) sets in before recruitment within 72 hours.\n* History of clinical findings\u002Fhospitalization due to heart failure within the past 6 months,\n* Albumin administration prior to randomization in the same hospital admission.\n* History of acute myocardial infarction (MI) within past 3 months.\n* Any clinical presentations or electrocardiography (ECG) findings suggestive of acute MI on current admission.\n* ECG evidence and\u002For clinical findings of 2nd or 3rd degree heart block or arrhythmias causing hemodynamic changes.\n* Echocardiogram done before intervention\u002Frandomization showing an ejection fraction of \\\u003C40%.\n* A creatinine level of \\>2.0 mg\u002Fdl or a creatinine clearance of \\\u003C50 ml\u002Fmin\n* Pregnancy, lactation, or parturition within previous 30 days\n* Any allergies to any ingredient in human albumin preparation.\n* A prior severe physical disability (mRS \\>2) that may hamper assessment of clinical outcome.\n* Advanced chronic obstructive pulmonary diseases (with FEV1 \\\u003C50%) may manifest as frequent episodes significantly affecting the overall quality of life.\n* Hepatic failure or suspected liver dysfunction due to deranged liver functions, decreased serum albumin levels, high bilirubin levels with\u002Fwithout peripheral edema and hepatic encephalopathy.\n* Patient has been already enrolled in another study involving a drug administration.\n* Patient suffering from terminal diseases with life expectancy \\\u003C 6 months\n* If patient speaks any other language in which consent has not been translated.\n* In case, patient drops out\u002Fwithdraws from study or transferred out of state of Qatar and therefore lost to follow up short of 3-month follow up.",{"count":647,"type":22},84,[25],"Aneurysmal subarachnoid hemorrhage (aSAH) is a dreadful acute neurological condition with overwhelmingly high rate of associated morbidities and mortality. Despite leaping advancement in neurosurgical techniques and imaging modalities, there is no substantiative improvement in overall prognosis for aSAH. Cerebral vasospasm remains the predominant cause of associated morbidities. Human albumin has been used in different neurological conditions including head trauma, intracerebral hemorrhages, and ischemic strokes with favorable outcome. However, its beneficial use in aSAH has not been sufficiently explored until recently a published systematic review by our team. In view of scarcity of published data and lack of robust evidence, our group has designed for the first ever RCT to compare the use human albumin-enhanced fluid management versus standard fluid therapy with crystalloids in patients with aSAH.\n\nThis single center open label, prospective, parallel group randomized control trial will be conducted at Hamad General Hospital, Doha-Qatar from August 2024 to July 2027. A sample size of 84 (42 in each arm) has been calculated to detect as sufficient to detect a clinically significant difference in modified Rankin Scale good score between two groups (human-albumin induced volume expansion therapy versus crystalloid only) for fluid management in aneurysmal subarachnoid hemorrhages patients. Primary outcome will be based on dichotomized modified Rankin scale \\[(Good grades (0-2) and poor grades (3-6)\\], while secondary outcome will include symptomatic vasospasm, transcranial doppler velocities, and Pulse Index Contour Cardiac Output (PiCCO) parameters.\n\nThe trial aims to provide firsthand evidence on the beneficial use of human albumin to achieve optimal fluid management regime to explore its potential role to improve clinical outcome in patients with aSAH.",[28],[652],"HASH trial, Human Albumin, Subarachnoid hemorrhage, Aneurysmal, Effectiveness, Clinical Outcome, Protocol","2024-08-09",{"date":655,"type":36},"2024-08-12",{"date":657,"type":22},"2024-08-01",{"date":659,"type":22},"2027-07-31",{"name":661,"class":275},"Hamad Medical Corporation"]